Novo Nordisk Stock Slips as CEO Faces Senate Inquiry Into Wegovy, Ozempic Prices

Key TakeawaysNovo Nordisk CEO Lars Fruergaard Jorgensen will testify Tuesday before a Senate panel looking into the drug maker's pricing of weight-loss drugs Wegovy and Ozempic.The committee accused the company of charging "outrageously high prices" for the treatments.Jorgensen has defended the costs, and said most Americans with insurance pay $25 a month for Wegovy. Novo Nordisk's (NVO) U.S.-listed shares lost ground Monday, a day before a Senate hearing on the costs of the company's popular weight-loss dr ...